Biocidal Activity of Tannic Acid-Prepared Silver Nanoparticles towards Pathogens Isolated from Patients with Exacerbations of Chronic Rhinosinusitis
Abstract
:1. Introduction
2. Results
2.1. Synthesis and Physicochemical Characteristics of TA-AgNPs
2.2. Bacterial Isolates
2.3. Determination of the Minimal Inhibitory Concentration (MIC)
2.4. Cytotoxicity of TA-AgNPs towards Human Primary Nasal Epithelial Cells (HNEpC)
3. Discussion
- (a)
- The study group included only patients with postoperative AECRS, so the results presented in this paper may not apply to bacterial exacerbations of CRS in patients who did not undergo sinus surgery;
- (b)
- Only aerobic species were included in the study;
- (c)
- In this study, we used one type of AgNPs (TA-AgNP). The properties of AgNPs obtained with different methods may vary;
- (d)
- This observational study was designed to estimate the prevalence of phenotypic resistance while the prevalence of resistance genes or cryptic resistance and determination of resistance mechanisms requires a more detailed exploration to explain the observed differences in sensitivity between bacterial isolates;
- (e)
- The results of in vitro tests of AgNPs efficacy are always affected by the media in which the experiment is conducted due to their interaction with ions, macromolecules and blood [10]. Therefore, further research on the interactions between the AgNPs and the secretions in the sinonasal cavities is necessary before their application in vivo.
4. Materials and Methods
4.1. Sample Collection
4.2. Bacterial Identification, Antibiotic Sensitivity Testing and Identification of Antibiotic Resistance Mechanisms
4.3. Synthesis of TA-AgNPs
4.4. Physicochemical Characteristics of TA-AgNPs
4.5. Determination of the Minimal Inhibitory Concentration (MIC) of TA-AgNPs by the Well Diffusion Method
4.6. In Vitro Primary Cell Culture and Cell Viability Assays
4.6.1. MTT Assay
4.6.2. Trypan Blue Exclusion
4.7. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Fokkens, W.J.; Lund, V.J.; Hopkins, C.; Hellings, P.W.; Kern, R.; Reitsma, S.; Toppila-Salmi, S.; Bernal-Sprekelsen, M.; Mullol, J.; Alobid, I.; et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020, 58 (Suppl. S29), 1–464. [Google Scholar] [CrossRef] [PubMed]
- Orlandi, R.R.; Kingdom, T.T.; Smith, T.L.; Bleier, B.; DeConde, A.; Luong, A.U.; Poetker, D.M.; Soler, Z.; Welch, K.C.; Wise, S.K.; et al. International consensus statement on allergy and rhinology: Rhinosinusitis. Int. Forum. Allergy Rhinol. 2020, 11, 213–739. [Google Scholar]
- Brook, I. Bacteriology of chronic sinusitis and acute exacerbation of chronic sinusitis. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 1099–1101. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, S.; Zheng, J. Antibacterial Activity of Silver Nanoparticles: Structural Effects. Adv. Healthc. Mater. 2018, 7, e1701503. [Google Scholar] [CrossRef]
- Gibała, A.; Żeliszewska, P.; Gosiewski, T.; Krawczyk, A.; Duraczyńska, D.; Szaleniec, J.; Szaleniec, M.; Oćwieja, M. Antibacterial and Antifungal Properties of Silver Nanoparticles-Effect of a Surface-Stabilizing Agent. Biomolecules 2021, 11, 1481. [Google Scholar] [CrossRef]
- Feizi, S.; Cooksley, C.M.; Bouras, G.S.; Prestidge, C.A.; Coenye, T.; Psaltis, A.J.; Wormald, P.J.; Vreugde, S. Colloidal silver combating pathogenic Pseudomonas aeruginosa and MRSA in chronic rhinosinusitis. Colloids Surf. B Biointerfaces 2021, 202, 111675. [Google Scholar] [CrossRef]
- Falconer, J.L.; Grainger, D.W. In vivo comparisons of silver nanoparticle and silver ion transport after intranasal delivery in mice. J. Control. Release 2018, 269, 1–9. [Google Scholar]
- Percival, S.L.; Salisbury, A.M.; Chen, R. Silver, biofilms and wounds: Resistance revisited. Crit. Rev. Microbiol. 2019, 45, 223–237. [Google Scholar] [CrossRef] [PubMed]
- Nino-Martinez, N.; Salas Orozco, M.F.; Martinez-Castanon, G.A.; Torres Mendez, F.; Ruiz, F. Molecular Mechanisms of Bacterial Resistance to Metal and Metal Oxide Nanoparticles. Int. J. Mol. Sci. 2019, 20, 2808. [Google Scholar]
- Joshi, A.S.; Singh, P.; Mijakovic, I. Interactions of Gold and Silver Nanoparticles with Bacterial Biofilms: Molecular Interactions behind Inhibition and Resistance. Int. J. Mol. Sci. 2020, 21, 7658. [Google Scholar] [CrossRef]
- Blanco Massani, M.; Klumpp, J.; Widmer, M.; Speck, C.; Nisple, M.; Lehmann, R.; Schuppler, M. Chromosomal Sil system contributes to silver resistance in E. coli ATCC 8739. Biometals 2018, 31, 1101–1114. [Google Scholar] [CrossRef] [PubMed]
- Ooi, M.L.; Richter, K.; Bennett, C.; Macias-Valle, L.; Vreugde, S.; Psaltis, A.J.; Wormald, P.J. Topical Colloidal Silver for the Treatment of Recalcitrant Chronic Rhinosinusitis. Front. Microbiol. 2018, 9, 720–727. [Google Scholar] [PubMed] [Green Version]
- Hyun, J.S.; Lee, B.S.; Ryu, H.Y.; Sung, J.H.; Chung, K.H.; Yu, I.J. Effects of repeated silver nanoparticles exposure on the histological structure and mucins of nasal respiratory mucosa in rats. Toxicol. Lett. 2008, 182, 24–28. [Google Scholar] [CrossRef] [PubMed]
- Genter, M.B.; Newman, N.C.; Shertzer, H.G.; Ali, S.F.; Bolon, B. Distribution and systemic effects of intranasally administered 25 nm silver nanoparticles in adult mice. Toxicol. Pathol. 2012, 40, 1004–1013. [Google Scholar] [CrossRef]
- Finley, P.J.; Norton, R.; Austin, C.; Mitchell, A.; Zank, S.; Durham, P. Unprecedented Silver Resistance in Clinically Isolated Enterobacteriaceae: Major Implications for Burn and Wound Management. Antimicrob. Agents Chemother. 2015, 59, 4734–4741. [Google Scholar] [CrossRef] [Green Version]
- Galdopórpora, J.M.; Ibar, A.; Tuttolomondo, M.V. Desimone, Dual-effect core–shell polyphenol coated silver nanoparticles for tissue engineering. Nano-Struct. Nano-Objects 2021, 26, 100716-24. [Google Scholar] [CrossRef]
- Rezazadeh, N.H.; Buazar, F.; Matroodi, S. Synergistic effects of combinatorial chitosan and polyphenol biomolecules on enhanced antibacterial activity of biofunctionalized silver nanoparticles. Sci. Rep. 2020, 10, 19615. [Google Scholar] [CrossRef]
- Kaczmarek, B. Tannic acid with antiviral and antibacterial activity as a promising component of biomaterials—A minireview. Materials 2020, 13, 3224–3237. [Google Scholar]
- Orłowski, P.; Kowalczyk, A.; Tomaszewska, E.; Ranoszek-Soliwoda, K.; Węgrzyn, A.; Grzesiak, J.; Celichowski, G.; Grobelny, J.; Errikson, K.; Krzyżowska, M. Antiviral activity of tannic acid modified silver nanoparticles: Potential to activate immune response in herpes genitalis. Viruses 2018, 10, 524. [Google Scholar] [CrossRef] [Green Version]
- Szymańska, E.; Orłowski, P.; Winnicka, K.; Tomaszewska, E.; Bąska, P.; Celichowski, G.; Grobelny, J.; Basa, A.; Krzyżowska, M. Multifunctional tannic acid/silver nanoparticle-based mucoadhesive hydrogel for improved local treatment of HSV infection: In vitro and in vivo studies. Int. J. Mol. Sci. 2018, 19, 387. [Google Scholar] [CrossRef] [Green Version]
- Haddad, M.; Gaudreault, R.; Sasseville, G.; Nguyen, P.T.; Wiebe, H.; Van De Ven, T.; Bourgault, S.; Mousseau, N.; Ramassamy, C. Molecular interactions of tannic acid with proteins associated with SARS-CoV-2 infectivity. Int. J. Mol. Sci. 2022, 23, 2643–2667. [Google Scholar] [PubMed]
- Mhlanga, P.; Perumal, P.O.; Somboro, A.M.; Amoako, D.G.; Khumalo, H.M.; Khan, R.B. Mechanistic insights into oxidative stress and apoptosis mediated by tannic acid in human liver hepatocellular carcinoma cells. Int. J. Mol. Sci. 2019, 20, 6145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sp, N.; Kang, D.Y.; Jo, E.S.; Rugamba, A.; Kim, W.S.; Park, Y.-M.; Hwang, D.-Y.; Yoo, J.-S.; Liu, Q.; Jang, K.-J.; et al. Tannic acid promotes TRAIL-induced extrinsic apoptosis by regulating mitochondrial ROS in human embryonic carcinoma cells. Cells 2020, 9, 282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Youness, R.A.; Kamel, R.; Elkasabgy, N.A.; Shao, P.; Farag, M.A. Recent advances in tannic acid (gallotannin) anticancer activities and drug delivery systems for efficacy improvement: A comprehensive review. Molecules 2021, 26, 1486–1501. [Google Scholar]
- Barbasz, A.; Oćwieja, M.; Barbasz, J. Cytotoxic activity of highly purified silver nanoparticles sol against cells of human immune system. Appl. Biochem. Biotechnol. 2015, 176, 817–834. [Google Scholar] [CrossRef]
- Ranoszek-Soliwoda, K.; Tomaszewska, E.; Socha, E.; Krzyczmonik, P.; Ignaczak, A.; Orlowski, P.; Krzyzowska, M.; Celichowski, G.; Grobelny, J. The role of tannic acid and sodium citrate in the synthesis of silver nanoparticles. J. Nanoparticle Res. 2017, 19, 273. [Google Scholar]
- Venkatesham, M.; Ayodhya, D.; Madhusudhan, A.; Santoshi Kumari, A.; Veerabhadram, G.; GirijaMangatayaru, K. A novel green synthesis of silver nanoparticles using gum karaya: Characterization, antimicrobial and catalytic activity studies. J. Clust. Sci. 2014, 25, 409–422. [Google Scholar] [CrossRef]
- Priya, D.B.; Asharani, I.V. Size dependent catalytic activity of actinodaphnemadraspatanabedd leaves mediated silver nanoparticles. J. Clust. Sci. 2017, 28, 1837–1856. [Google Scholar]
- Oćwieja, M.; Popov, A.; Adamczyk, Z.; Morga, M.; Ramanaviciene, A.; Ramanavicius, A. Deposition of silver nanoparticles from suspensions containing tannic acid. Colloids Surf. Aphysicochem. Eng. Asp. 2015, 477, 70–76. [Google Scholar] [CrossRef]
- Magaldi, S.; Mata-Essayag, S.; HartungdeCapriles, C.; Perez, C.; Colella, M.T.; Olaizola, C.; Ontiveros, Y. Well diffusion for antifungal susceptibilitytesting. Int. J. Infect. Dis. 2004, 8, 39–45. [Google Scholar]
- Balouiri, M.; Sadiki, M.; Ibnsouda, S.K. Methods for in vitro evaluating antimicrobial activity: A review. J. Pharm. Anal. 2016, 6, 71–79. [Google Scholar] [PubMed] [Green Version]
- Sathishkumar, G.; Kasi, G.; Zhang, K.; Kang, E.T.; Xu, L.; Yu, Y. Recent progress in Tannic Acid-driven antimicrobial/antifouling surface coating strategies. J. Mater. Chem. B 2022, 10, 2296–2315. [Google Scholar] [CrossRef] [PubMed]
- Chung, K.-T.; Stevens, S.E.; Lin, W.-F.; Wei, C.I. Growth inhibition of selected food-borne bacteria by tannic acid, propyl gallate and related compounds. Lett. Appl. Microbiol. 1993, 17, 29–32. [Google Scholar]
- Kim, J.S.; Kuk, E.; Yu, K.N.; Kim, J.H.; Park, S.J.; Lee, H.; Kim, S.H.; Park, Y.K.; Park, Y.H.; Hwang, C.-Y.; et al. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007, 3, 95–101. [Google Scholar] [CrossRef] [PubMed]
- Li, W.R.; Xie, X.B.; Shi, Q.S.; Duan, S.S.; Ouyang, Y.S.; Chen, Y.B. Antibacterial effect of silver nanoparticles on Staphylococcus aureus. Biometals 2011, 24, 135–141. [Google Scholar]
- Yuan, Y.G.; Peng, Q.L.; Gurunathan, S. Effects of Silver Nanoparticles on Multiple Drug-Resistant Strains of Staphylococcus aureus and Pseudomonas aeruginosa from Mastitis-Infected Goats: An Alternative Approach for Antimicrobial Therapy. Int. J. Mol. Sci. 2017, 18, 569. [Google Scholar] [CrossRef] [Green Version]
- Mirzajani, F.; Ghassempour, A.; Aliahmadi, A.; Esmaeili, M.A. Antibacterial effect of silver nanoparticles on Staphylococcus aureus. Res. Microbiol. 2011, 162, 542–549. [Google Scholar] [CrossRef]
- Gangwar, C.; Yaseen, B.; Nayak, R.; Praveen, S.; Singh, N.K.; Sarkar, J.; Banerjee, M.; Naik, R.M. Silver nanoparticles fabricated by tannic acid for their antimicrobial and anticancerous activity. Inorg. Chem. Commun. 2022, 141, 109532. [Google Scholar] [CrossRef]
- Valgas, C.; Machado de Souza, S.; Smania, E.F.A.; Smania, A. Screening methods to determine antibterial activity of natural products. Brazil J. Microbiol. 2007, 38, 369–380. [Google Scholar] [CrossRef] [Green Version]
- Kim, T.Y.; Cha, S.H.; Cho, S.; Park, Y. Tannic acid-mediated green synthesis of antibacterial silver nanoparticles. Arch. Pharm. Res. 2016, 39, 465–473. [Google Scholar]
- Chatterjee, T.; Chatterjee, B.K.; Majumdar, D.; Chakrabarti, P. Antibacterial effect of silver nanoparticles and the modeling of bacterial growth kinetics using a modified Gompertz model. Biochim. Biophys. Acta 2015, 1850, 299–306. [Google Scholar] [CrossRef] [PubMed]
- Tian, S.; Hu, Y.; Chen, X.; Liu, C.; Xue, Y.; Han, B. Green synthesis of silver nanoparticles using sodium alginate and tannic acid: Characterization and anti-S. aureus activity. Int. J. Biol. Macromol. 2022, 19, 515–522. [Google Scholar]
- La Spina, R.; Mehn, D.; Fumagalli, F.; Holland, M.; Reniero, F.; Rossi, F.; Gilliland, D. Synthesis of citrate-stabilized silver nanoparticles modified by thermal and ph preconditioned tannic acid. Nanomaterials 2020, 10, 2031–2047. [Google Scholar] [PubMed]
- Liu, L.; Ge, C.; Zhang, Y.; Ma, W.; Su, X.; Chen, L.; Li, S.; Wang, L.; Mu, X.; Xu, Y. Tannic acid-modified silver nanoparticles for enhancing anti-biofilm activities and modulating biofilm formation. Biomater. Sci. 2020, 8, 4852–4860. [Google Scholar] [CrossRef]
- Li, X.Z.; Nikaido, H.; Williams, K.E. Silver-resistant mutants of Escherichia coli display active efflux of Ag+ and are deficient in porins. J. Bacteriol. 1997, 179, 6127–6132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- George, S.; Tay, I.; Phue, W.H.; Gardner, H.; Sukumaran, B. Enhancing the Bioavailability of Silver Through Nanotechnology Approaches Could Overcome Efflux Pump Mediated Silver Resistance in Methicillin Resistant Staphylococcus aureus. J. Biomed. Nanotechnol. 2019, 15, 2216–2228. [Google Scholar] [CrossRef] [PubMed]
- Woods, E.J.; Cochrane, C.A.; Percival, S.L. Prevalence of silver resistance genes in bacteria isolated from human and horse wounds. Vet. Microbiol. 2009, 138, 325–329. [Google Scholar] [PubMed] [Green Version]
- Percival, S.L.; Woods, E.; Nutekpor, M.; Bowler, P.; Radford, A.; Cochrane, C. Prevalence of silver resistance in bacteria isolated from diabetic foot ulcers and efficacy of silver-containing wound dressings. Ostomy Wound Manag. 2008, 54, 30–40. [Google Scholar]
- Loh, J.V.; Percival, S.L.; Woods, E.J.; Williams, N.J.; Cochrane, C.A. Silver resistance in MRSA isolated from wound and nasal sources in humans and animals. Int. Wound J. 2009, 6, 32–38. [Google Scholar] [CrossRef]
- Ip, M.; Lui, S.L.; Chau, S.S.; Lung, I.; Burd, A. The prevalence of resistance to silver in a Burns unit. J. Hosp. Infect. 2006, 63, 342–344. [Google Scholar]
- Finley, P.J.; Peterson, A.; Huckfeldt, R.E. The prevalence of phenotypic silver resistance in clinical isolates. Wounds 2013, 25, 84–88. [Google Scholar] [PubMed]
- Elkrewi, E.; Randall, C.P.; Ooi, N.; Cottell, J.L.; O’Neill, A.J. Cryptic silver resistance is prevalent and readily activated in certain Gram-negative pathogens. J. Antimicrob. Chemother. 2017, 72, 3043–3046. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chernousova, S.; Epple, M. Silver as antibacterial agent: Ion, nanoparticle, and metal. Angew. Chem. Int. Ed. 2013, 52, 1636–1653. [Google Scholar] [CrossRef] [PubMed]
- Foldbjerg, R.; Dang, D.A.; Autrup, H. Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch. Toxicol. 2011, 85, 743–750. [Google Scholar]
- Miura, N.; Shinohara, Y. Cytotoxic effect and apoptosis induction by silver nanoparticles in HeLa cells. Biochem. Biophys. Res. Commun. 2009, 390, 733–737. [Google Scholar]
- Chen, S.Y.; Huang, M.T.; Pender, S.L.F.; Ruslin, M.; Chou, H.H.; Ou, K.L. The application of silver nanoparticles on developing potential treatment for chronic rhinosinusitis: Antibacterial action and cytotoxicity effect on human nasal epithelial cell model. Mater. Sci. Eng. C Mater. Biol. Appl. 2017, 80, 624–630. [Google Scholar] [CrossRef]
- Costa, C.P.; Barreiro, S.; Moreira, J.N.; Silva, R.; Almeida, H.; Sousa Lobo, J.M.; Silva, A.C. In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN). Pharmaceuticals 2021, 14, 711–734. [Google Scholar]
- Chen, L.; Wu, M.; Jiang, S.; Zhang, Y.; Li, R.; Lu, Y.; Liu, L.; Wu, G.; Liu, Y.; Xie, L.; et al. Skin Toxicity Assessment of Silver Nanoparticles in a 3D Epidermal Model Compared to 2D Keratinocytes. Int. J. Nanomed. 2019, 14, 9707–9719. [Google Scholar] [CrossRef] [Green Version]
- Zavala, J.; O’Brien, B.; Lichtveld, K.; Sexton, K.G.; Rusyn, I.; Jaspers, I.; Vizuete, W. Assessment of biological responses of EpiAirway 3-D cell constructs versus A549 cells for determining toxicity of ambient air pollution. Inhal. Toxicol. 2016, 28, 251–259. [Google Scholar] [CrossRef] [Green Version]
- Luengen, A.E.; Kniebs, C.; Buhl, E.M.; Cornelissen, C.G.; Schmitz-Rode, T.; Jockenhoevel, S.; Thiebes, A.L. Choosing the Right Differentiation Medium to Develop Mucociliary Phenotype of Primary Nasal Epithelial Cells in Vitro. Sci. Rep. 2020, 10, 6963–6974. [Google Scholar]
- Muller, L.; Brighton, L.E.; Carson, J.L.; Fischer, W.A.; Jaspers, I. Culturing of human nasal epithelial cells at the air liquid interface. J. Vis. Exp. 2013, 80, e50646. [Google Scholar]
- Mistry, A.; Stolnik, S.; Illum, L. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 2009, 379, 146–157. [Google Scholar] [PubMed]
- Wen, R.; Yang, X.; Hu, L.; Sun, C.; Zhou, Q.; Jiang, G. Brain-targeted distribution and high retention of silver by chronic intranasal instillation of silver nanoparticles and ions in Sprague-Dawley rats. J. Appl. Toxicol. 2016, 36, 445–453. [Google Scholar] [CrossRef] [PubMed]
- Fokkens, W.J.; Lund, V.J.; Mullol, J.; Bachert, C.; Alobid, I.; Baroody, F.; Cohen, N.; Cervin, A.; Douglas, R.; Gevaert, P.; et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012, 50, 1–298. [Google Scholar] [PubMed] [Green Version]
- Orlandi, R.R.; Kingdom, T.T.; Hwang, P.H.; Smith, T.L.; Alt, J.A.; Baroody, F.M.; Batra, P.S.; Bernal-Sprekelsen, M.; Bhattacharyya, N.; Chandra, R.K.; et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int. Forum. Allergy Rhinol. 2016, 6 (Suppl. 1), S22–S209. [Google Scholar]
- Szaleniec, J.; Gibala, A.; Pobiega, M.; Parasion, S.; Skladzien, J.; Strek, P.; Gosiewski, T.; Szaleniec, M. Exacerbations of Chronic Rhinosinusitis-Microbiology and Perspectives of Phage Therapy. Antibiotics 2018, 8, 175–188. [Google Scholar]
- Hopper, D.J.; Kaderbhai, M.A. 2,4′-Dihydroxyacetophenone dioxygenase (EC 1.13.11.41) from Alcaligenes sp. 4HAP: A novel enzyme with an atypical dioxygenase sequence. Biochem. J. 1999, 344, 397–402. [Google Scholar] [CrossRef]
- Hopper, D.J.; Kaderbhai, M.A. The quinohaemoproteinlupanine hydroxylase from Pseudomonas putida. Biochim. Biophys. Acta-Proteins Proteom. 2003, 1647, 110–115. [Google Scholar] [CrossRef] [PubMed]
- Oćwieja, M.; Adamczyk, Z.; Morga, M.; Michna, A. High density silver nanoparticle monolayers produced by colloid self-assembly on polyelectrolyte supporting layers. J. Colloid Interface Sci. 2011, 364, 39–48. [Google Scholar]
- Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63. [Google Scholar] [CrossRef]
- Strober, W. Trypan Blue Exclusion Test of Cell Viability. Curr. Protoc. Immunol. 2015, 111, A3.B1–A3.B3. [Google Scholar] [CrossRef] [PubMed]
Species (No. of Clinical Isolates) | Reference Strain | Reference Isolates | |||
---|---|---|---|---|---|
Median | Min | Max | Interquartile Range | ||
Staphylococcus aureus (30) | 5 | 10 | 5 | 40 | 15 |
Pseudomonas aeruginosa (5) | 10 | 5 | 5 | 20 | 5 |
Escherichia coli (4) | 5 | 25 | 10 | 25 | 7.5 |
Klebsiella pneumoniae (3) | 5 | 25 | 10 | 30 | 20 |
Klebsiella oxytoca (2) | - | 10 | 40 | - | |
Acinetobacter baumannii (2) | - | 10 | 10 | - | |
Serratia marcescens (1) | - | 25 | 25 | - | |
Enterobacter cloacae (1) | - | 30 | 30 | - | |
All clinical isolates (48) | 10 | 5 | 40 | 15 | |
All Gram-positive clinical isolates (30) | 10 | 5 | 40 | 15 | |
All Gram-negative clinical isolates (18) | 15 | 5 | 40 | 15 |
Mechanisms of Antibiotic Resistance (Number of Bacterial Isolates) | Median | Min | Max | Interquartile Range |
---|---|---|---|---|
no mechanisms of antibiotic resistance (34) | 10 | 5 | 40 | 15 |
with mechanisms of antibiotic resistance (14) | 17.5 | 5 | 40 | 15 |
ESBL (5) | 25 | 25 | 30 | 2.5 |
MRSA + MLS (2) | - | 5 | 25 | - |
MLS (7) | 10 | 10 | 40 | 15 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Szaleniec, J.; Gibała, A.; Stalińska, J.; Oćwieja, M.; Żeliszewska, P.; Drukała, J.; Szaleniec, M.; Gosiewski, T. Biocidal Activity of Tannic Acid-Prepared Silver Nanoparticles towards Pathogens Isolated from Patients with Exacerbations of Chronic Rhinosinusitis. Int. J. Mol. Sci. 2022, 23, 15411. https://doi.org/10.3390/ijms232315411
Szaleniec J, Gibała A, Stalińska J, Oćwieja M, Żeliszewska P, Drukała J, Szaleniec M, Gosiewski T. Biocidal Activity of Tannic Acid-Prepared Silver Nanoparticles towards Pathogens Isolated from Patients with Exacerbations of Chronic Rhinosinusitis. International Journal of Molecular Sciences. 2022; 23(23):15411. https://doi.org/10.3390/ijms232315411
Chicago/Turabian StyleSzaleniec, Joanna, Agnieszka Gibała, Joanna Stalińska, Magdalena Oćwieja, Paulina Żeliszewska, Justyna Drukała, Maciej Szaleniec, and Tomasz Gosiewski. 2022. "Biocidal Activity of Tannic Acid-Prepared Silver Nanoparticles towards Pathogens Isolated from Patients with Exacerbations of Chronic Rhinosinusitis" International Journal of Molecular Sciences 23, no. 23: 15411. https://doi.org/10.3390/ijms232315411